Partial Reduction of Human FOXP3+ CD4 T Cells In Vivo After CD25-directed Recombinant Immunotoxin Administration

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

2003 • 7,470 citations

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

2004 • 4,872 citations

N<scp>aturally</scp>A<scp>rising</scp>CD4⁺R<scp>egulatory</scp>T C<scp>ells for</scp>I<scp>mmunologic</scp>S<scp>elf</scp>-T<scp>olerance and</scp>N<scp>egative</scp>C<scp>ontrol of</scp>I<scp>mmune</scp>R<scp>esponses</scp>

2003 • 3,323 citations

The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3

2001 • 3,260 citations

Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self

2005 • 2,667 citations

Regulatory T cells, tumour immunity and immunotherapy

2006 • 2,009 citations

Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma

2005 • 1,613 citations

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

2003 • 1,564 citations

Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity

1999 • 1,475 citations

Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

1999 • 1,066 citations

Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses

2001 • 1,033 citations

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

2005 • 998 citations

Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

2005 • 997 citations

Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development

2006 • 773 citations

CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells

2005 • 741 citations

Foxp3 Expressing CD4+CD25high Regulatory T Cells Are Overrepresented in Human Metastatic Melanoma Lymph Nodes and Inhibit the Function of Infiltrating T Cells

2004 • 680 citations

Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma

2001 • 612 citations

Tumor-Specific Human CD4+ Regulatory T Cells and Their Ligands

2004 • 525 citations

Cutting Edge: Depletion of CD4+CD25+ Regulatory T Cells Is Necessary, But Not Sufficient, for Induction of Organ-Specific Autoimmune Disease

2002 • 332 citations

Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade

2005 • 331 citations

Factors Associated With Response to High-Dose Interleukin-2 in Patients With Metastatic Melanoma

2001 • 308 citations

Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma

2005 • 293 citations

Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens

2002 • 289 citations

Phase I immunotoxin trial in patients with B-cell lymphoma.

1991 • 289 citations

Depletion of CD4⁺CD25⁺ human regulatory T cells in vivo: Kinetics of Treg depletion and alterations in immune functions in vivo and in vitro

2007 • 244 citations

Depletion of CD4+CD25+ Regulatory Cells Augments the Generation of Specific Immune T Cells in Tumor-Draining Lymph Nodes

2002 • 206 citations

Impact of Cytokine Administration on the Generation of Antitumor Reactivity in Patients with Metastatic Melanoma Receiving a Peptide Vaccine

1999 • 188 citations

Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interkeukin-2

1998 • 188 citations

Administration of a CD25-Directed Immunotoxin, LMB-2, to Patients with Metastatic Melanoma Induces a Selective Partial Reduction in Regulatory T Cells In Vivo

2007 • 163 citations

Dendritic Cells Loaded with Stressed Tumor Cells Elicit Long-Lasting Protective Tumor Immunity in Mice Depleted of CD4+CD25+ Regulatory T Cells

2005 • 161 citations

Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.

1988 • 155 citations

Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders.

1990 • 150 citations

Vaccination against the Forkhead Family Transcription Factor Foxp3 Enhances Tumor Immunity

2007 • 146 citations

A Phase-I Study of an Anti-CD25 Ricin A-Chain Immunotoxin (RFT5-SMPT-dgA) in Patients With Refractory Hodgkin's Lymphoma

1997 • 142 citations

CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens.

2003 • 139 citations

DAB389IL-2 (ONTAK): A Novel Fusion Toxin Therapy for Lymphoma

2000 • 120 citations

Interleukin 2 receptor‐targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin‐related interleukin 2 fusion protein into cells

1990 • 117 citations

Phase II Study of Denileukin Diftitox for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

2004 • 96 citations

Following Anti-CD25 Treatment, A Functional CD4+CD25+ Regulatory T-Cell Pool Is Present in Renal Transplant Recipients

2006 • 90 citations

IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases.

1987 • 83 citations

Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin

2000 • 75 citations

Selective Elimination of Human Regulatory T Lymphocytes In Vitro With the Recombinant Immunotoxin LMB-2

2006 • 75 citations

Recombinant toxins for the treatment of cancer.

2003 • 73 citations

DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma

1998 • 68 citations

Inability to Mediate Prolonged Reduction of Regulatory T Cells After Transfer of Autologous CD25-depleted PBMC and Interleukin-2 After Lymphodepleting Chemotherapy

2007 • 61 citations

Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation

2004 • 60 citations

Sequential effects of interleukin 2-diphtheria toxin fusion protein on T-cell activation.

1989 • 49 citations

Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins

1994 • 40 citations

Large-Scale Depletion of CD25+ Regulatory T Cells from Patient Leukapheresis Samples

2005 • 39 citations

Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins

1994 • 33 citations

Recombinant immunotoxins for the treatment of haematological malignancies

2004 • 16 citations

A KINETIC ANALYSIS OF THE EFFECTS OF INTERLEUKIN-2 DIPHTHERIA TOXIN FUSION PROTEIN UPON ACTIVATED T CELLS

1990 • 10 citations

Remission of Follicular Non-Hodgkin's Lymphoma with Denileukin Diftitox (ONTAK ® ) After Progression During Rituximab, CHOP and Fludarabine Therapy

2003 • 8 citations